ALTANA Research Institute (ARI) (http://www.ari.altanapharma.com) is the research division of ALTANA Pharma US, Inc. and combines the dynamic spirit of a start-up with the resources of an international leader. Employing a state-of-the-art automated genomics and proteomics research capabilities, the ARI team discovered novel targets that are now being used to develop new mechanism driven therapeutic approaches for the treatment of inflammatory/respiratory diseases, gastrointestinal disorders and cancer. By adding medicinal chemistry and a strong focus in pharmacological sciences, the institute is now transforming into a research entity with a sharp indication focus in respiratory. As a research-driven, international pharmaceutical company with more than 30 subsidiaries world-wide, ALTANA Pharma AG (http://www.altanapharma.com), headquartered in Constance/Germany, invests about 20% of its earnings from sales into R&D (2005 research expenditure $560M) and has been experiencing remarkable growth (about $2.8 billion of sales in 2005 - up 12% from 2004).
Last Updated: 04-06-2006